I

Irmandade da Santa Casa de Misericordia de Porto Alegre | Research Center

Research site
(Unclaimed)
Location
Independencia 155, Porto Alegre, Rio Grande do Sul, Brazil

Site insights

Top conditions

Top treatments

Pegcetacoplan
Ipilimumab
Leucovorin
INCB099280
PF-02341066
Bevacizumab
Sunitinib
Pembrolizumab
Bardoxolone Methyl
LY3009104

Parent organization

This site is a part of Irmandade da Santa Casa de Misericordia de Porto Alegre

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 41 total trials

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

This study is about an anticancer drug called ponatinib which is a tyrosine kinase inhibitor given with chemotherapy to children, teenagers, and youn...

Active, not recruiting
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
Ph+ Mixed Phenotype Acute Leukemia (MPAL)
Drug: Chemotherapy Agents
Drug: Ponatinib

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Enrolling
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab
Locations recently updated

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Enrolling
Gastroesophageal Adenocarcinoma
Gastric Neoplasms
Drug: Tislelizumab
Drug: Capecitabine

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting
Metastatic Adenocarcinoma of the Pancreas
Drug: Leucovorin
Drug: Gemcitabine

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Enrolling
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: INCB099280
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab comp...

Enrolling
Childhood Idiopathic Nephrotic Syndrome
Drug: Diphenhydramine Hydrochloride
Drug: MMF

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment this month
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Enrolling
Melanoma
Renal Cell Carcinoma (RCC)
Drug: INCB 99280 with Ipilimumab
Locations recently updated

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tum...

Enrolling
Cancer
Drug: Temozolomide
Drug: Capecitabine

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Other: Placebo
Drug: Pegcetacoplan

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients wh...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Drug: Pegcetacoplan

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Enrolling
Non-small Cell Lung Cancer
Drug: Domvanalimab
Drug: Nab-paclitaxel

Trial sponsors

Pfizer logo
A
Incyte logo
Lilly logo
Amgen logo
Reata Pharmaceuticals logo
AbbVie logo
Acceleron Pharma logo
Astellas logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems